1030
KLINICKÁ341804001074588109168189242288347
FARMAKOLOGIE709804001074291138211265312372415474533554598
A13288040010753
FARMACIE1403804001074191138210265316336380
/18298040010732
Klin190680400107446583131
Farmakol2057804001074278105179220258305325
Farm.2402804001074178104179195
2025;39(3):165-1702617804001074487128172185229271295337359373410449492520558595637
/32998040010731
www.klinickafarmakologie.cz4568804001076513320121425327329234035839843647950254457164568672477179183988990895196610061045
1701338020012657109165
PŘEHLEDOVÉ341200012660124182256312369444520587645
ČLÁNKY1008200012660115187259327395
Léčba3413600106296196132172
polymorbidních52936001063273105138191232268304322361402420454495
pacientů104036001063369103120152193226267
s1323360010630
roztroušenou136936001063474106139175216257289321362403444
sklerózou18293600106306697129165206237276317
18.343610085356883
Thormann4386100833270108129186217254291
A,7416100834154
Sřrensen807610083325273106143169203240
PS,1059610083346679
Koch-Henriksen11506100833471102139161206240277298313342370404441
N,16036100834456
et16716100833455
al.1738610083324759
Comorbidity18096100833975132170190343710083385390105127159
in5147100831451
multiple5777100835693108129144182197231
sclerosis819710083265772106126162188202227
is10587100831540
associated1110710083315782119151165196217250288
with1410710083506586123
diagnostic1545710083385283121158195221243258289
delays1846710083377186117147173
and3438100833270109
increased467810083155385106140172199234273
mortality.7558100835896118142175191205228262272
Neurology.10428100834580117139176192230269302312
2017;89(16):1668-1675.13698100833468100129139174209228259291309321350382417453475506537570603615
19.343910085366982
Zhang4389100833876108146185
T,6369100833241
Tremlett690910083335084142158192215239
H,9429100834457
Leung10129100833165103141180
S,12059100833345
et12639100833457
al.1333910083324760
Examining1406910083326598155171209224261300
the1719910083226095
effects1827910083345473107140164192
of34310100833756
comorbidities41110100833167124162183222237275290311326360387
on81010100833774
disease-modifying8971010083375277112143169203226283321360375393427442479518
therapy14271010083215993114146185215
initiation1654101008315526789103135156171208246
and191210100833169107
choice34311100833169107123155189
in54711100831552
MS.61511100835487100
Mult73111100835492107130
Scler8761110083336580115136
Relat10281110083357086118139
Disord.11831110083456187125147185198
2016;8:146-152.139611100833468100131144179191221252288312342372406418
20.3431210085367287
Magyari44512100835487126158191212228
M,68812100835468
Sřrensen7711210083325374109147173208246
PS.10321210083356881
Comorbidity112912100833976135173195234250289304326360
in150412100831553
Multiple157212100835492107130145184200235
Sclerosis.18221210083336580115136173343131008326416781
Front4391310083325289128149
Neurol.60413100834479117138175191204
2020;11:851.82413100833468101135148178205214249283314323
21.3431410085367082
Geraldes44214100834479100133149188223249
R,70914100833549
Ciccarelli7761410083405587118151172206221237252
O,104514100834758
Barkhof11211410083356889120159197217
F,135514100833238
et141114100833456
al.14851410083314760
The156214100833372107
current16871410083316990112146184205
role19101410083205874108
of34315100833757
MRI41815100835591106
in54315100831553
differentiating614151008338537392127148182220241257289310326364403
multiple103515100835895111133148187203238
sclerosis12921510083265873108129167193208234
from15451510083184078136
its17001510083143764
imaging178315100831572105144159197236
mimics.34316100835772130145177205219
Pract5771610083355689121145
Neurol.73716100834580118139176192205
2018;18(6):441-452.95716100833469100131144174205224257275287321358389407444477510522
22.3431710085367187
Marrie44217100835486107128143177
RA,6321710083357791
Rudick73617100833572110125156186
R,93517100833548
Horwitz99617100834381102155170192222
R,123117100833549
et129217100833456
al.13601710083314759
Vascular14321710083356692123161176207228
comorbidity167217100833168125163184223238277292314347
is34318100831541
associated3961810083325985123156171203224258298
with7061810083516689127
more84618100835795117151
rapid10101810083205392108146
disability11691810083385379112151167182197219253
progression14351810083386097137158192218245260297336
in178418100831452
multiple1849181008357951101321483431910083395589
sclerosis.4481910083265873108129167193208234248
Neurology.71119100834580118139176192230270302312
2010;74(13):1041-1047.103819100833468100132144177208227259289306318348379415446464495527563595601
23.3432010085367388
Mowry45120100835593145167201
EM,67220100833389102
Waubant79520100835789127166199238259
E,107520100833346
McCulloch114120100835588129166181197235268306
CE,14682010083407386
et157520100833456
al.16522010083324760
Vitamin17332010083365275108166181219
D1973201008345
status3432110083264982104142168
predicts5282110083396195134149181205233
new77821100833873124
brain9192110083396194109147
magnetic108321100835790129167202224239271
resonance13722110083205481119158190228260294
imaging168321100831573105144159197236
activity193621100833264343221008322376985108141
in50022100831452
multiple56822100835795110132148187203237
sclerosis.8212210083265873108129167193208234248
Ann108422100834179117
Neurol.121722100834479117138176191204
2012;72(2):234-240.143722100833468100130142175209227260278290325360396419450481517530
24.3432310085377490
Feinstein4592310083336986125153178214230270
A,75523100834258
Magalhaes83923100835690131165182222256292321
S,118623100833448
Richard12602310083365387127161183223
JF,15102310083255966
et160323100833558
al.16882310083324963
The177723100833475112
link19152310083153271103
between3432410083397598152187223261
multiple62524100835897112135151190207242
sclerosis8882410083265975110132170197212238
and114724100833371111
depression.127924100833874113135170197224240278317331
Nat163124100834578100
Rev175224100833671104
Neurol.187724100834581119343251008321587487
2014;10(9):507-517.44525100833468100131143173205224257275287322356389407441472502508
25.3432610085367286
Tettey4422610083326385109143174
P,62926100833539
Simpson68126100833247104143170208246
S939261008333
Jr,9852610083244554
Taylor10522610083336091107145166
BV,12312610083357179
et132326100833456
al.13922610083324760
An146426100834179
approach155626100833170110131168201233270
to183926100832258
studying191026100832649873432710083386985123161
co-occurring5172710083316790130162193230251272288325364
autoimmune8942710083316891127142200257294332366
diseases12732710083385379113145171206232
in151827100831452
multiple158327100835794109131146185200235
sclerosis.18312710083265773107128165343281008326416781
Mult43928100835492108130
Scler5842810083336580115136
Relat7362810083357086118140
Disord.8912810083456187125147185198
2014;3(3):254-265.110428100833569100131143178196230247259294329364387418452486498
26.3432910085367187
Luna44729100833168106139
G,60329100834357
Alping6762910083415796111149188
P,88129100833540
Burman9372910083367495153186224
J,117729100832537
et123029100833457
al.13032910083324860
Infection13802910083155372106139163178216255
Risks16522910083355177107135
Among180429100834199137176215
Patients3433010083356687102136173194221
With5773010083567294131
Multiple72130100835391105127142180196230
Sclerosis9633010083326479113134170196211236
Treated12123010083324882113134167206
With14303010083577395132
Fingolimod,15743010083324784122160175190246284323335
Natalizumab,192130100834476343311008322547085114152210242281294
Rituximab,6533110083355173111143158216248287300
and96931100833270109
Injectable10953110083145267102135159192231247282
Therapies.139331100833372107128161200216251278291
JAMA170131100832464119161
Neurol.187931100834580117343321008321587487
2020;77(2):184-191.44532100833468101135148181216232266284296325356393416447477509518
27.3433310085367180
Skou44033100833262100138
ST,5953310083336776
Mair68833100835587102123
FS,8293310083326476
Fortin9233310083326991116131169
M,110933100835468
et119433100833456
al.12673310083324861
Multimorbidity.134533100835492107130145203241263302318357372394428438
Nat18003310083457799
Rev191633100833671103
Dis3433410083456187
Primers.4453410083355672129164186213227
2022;8:48.68734100833468101136148183196230266279
28.3433510085367390
Cree4543510083416297133
BAC,60835100833678118132
Hollenbach76135100834584100116152191231264297336
JA,11183510083256680
Bove122035100833575108143
R,138435100833650
et145535100833558
al.15343510083324862
Silent1617351008333486499138160
progression179935100833961991401621963433610083275571110151
in51736100831555
disease5963610083395583119153181217
activity–free8373610083336692108142159183218256277300336373
relapsing12343610083215773107148176192232272
MS.153036100835691105
Ann165936100834282121
Neurol.180436100834683122145184201215
2019;85(5):653-666.34337100833468100130143178212230263282294329363396418455491526540
29.3433810085377488
Braley4533810083365993109145178
TJ,6523810083345668
Segal74238100833370111144160
BM.92438100833693108
Obstructive105338100834889117141164203237262278312347
sleep14223810083264279115156
apnea159938100833374113150183
is180338100831542
associated186738100833260881273433910083314779101136176
with5393910083516790129
fatigue688391008319537590130168203
in91239100831553
multiple98639100835896111134150189205241
sclerosis.12473910083275975110132170197212238252
J1520391008324
Clin15653910083405671109
Sleep16953910083334884120159
Med.187539100835591131144
2014;10(2):155-162.34340100833468100131143173204224258276288318348380402433464498510
30.3434110085367185
Kurth4434110083357190114150
T,61041100833240
Mohamed66641100835491128159216249288
S,97041100833244
Maillard10304110083548699113127158177214
P,126041100833539
et131541100833455
al.13864110083324657
Headache,145941100834478109146177208245278289
migraine,176441100835771108128160173210244254
and34342100833167104
structural4574210083264767103133155191210241255
brain7224210083385788102138
lesions869421008315487386121158182
and106142100833167104
function:11754210083185590121143156192229239
population-based142442100833875112148162192212225261298318356387412445482
Epidemiology1916421008332698334343100833872128142178193230268298
of65343100833856
Vascular7214310083356590121157171202222
Ageing–MRI95543100834178111125162199234289324338
study.13054310083264885122153161
BMJ.147843100833689114125
2011;342:c7357.16154310083346797123130164198229240270303335367399404
31.3434410085366981
Harding4384410083447698136151189228
K,67944100833550
Williams7424410083587489104119151209235
O,99144100834758
Willis10634410083577388104119145
M,122144100835568
et130344100833456
al.13734410083314760
Clinical14464410083405570108123155188203
outcomes16634410083377598129165224259286
of196244100833757
escalation3434510083346194127143175197213251290
vs65445100833259
early7344510083346688104136
intensive8904510083155375109148175190222257
disease-modifying11684510083385480115148174210233292331371387406441457495535
therapy17234510083226196118151190222
in196645100831553
MS.34346100835487101
JAMA45946100832464120162
Neurol.63646100834580117139176192205
2019;76(5):536-541.85646100833468100130143176208227260279291326359393417451486516526
32.3434710085367186
He44447100834479
A,53847100834055
Merkel60747100835590111141176191
B,81347100833548
Brown8754710083355794145184
JWL,107347100832483115129
et121647100833456
al.12874710083324760
Timing136147100833350107122160199
of157547100833756
high-efficacy16464710083375291129152188206224242274307339373
therapy3434810083226095116149188219
for5794810083185677
multiple67348100835795110132148187203237
sclerosis:9274810083265873108129167193208234247
a1190481008332
retrospective1238481008321557799136163201237270294309342376
observational163048100833777104139160195228249265303341373389
cohort34349100833168107145167191
study.5504910083264987126158168
Lancet73349100833165103135169191
Neurol.93949100834580118139176192205
2020;19(4):307-316.115949100833569102136148179209228261278290325360393411444474506519
33.3435010085367186
Selmaj4505010083336884142174190
K,66050100833650
Cree7315010083406196131
BAC,88350100833577116129
Barnett10335010083356890129164186211
M,126550100835468
et135450100833456
al.14315010083324760
Multiple151250100835593108131146186202237
sclerosis:17695010083275975110131169196211237250
time3435110083223795131
for4955110083185678
early5945110083346687103136
treatment7505110083224478110132191226265287
with10575110083516790128
high-efficacy12065110083385392131153190209227245277310343377
agents.160351100833272107145167195209
J1833511008324
Neurol.187851100834580118343521008321587487
2024;271(1):105-115.44552100833468101133145180213245260292306318348380414436467494524536
34.3435310085367388
Zeposia44753100833871111149176191223
(ozanimod)6865310083185583116154169227265305324
–1026531008335
Summary107753100833370128186218239273
of136653100833756
Product14385310083355693133170203227
Characteristics168153100833977110131164196220254275291317343541008322376997
(SmPC)45654100831950108144184205
[Internet].677541008319357294128149188223245262274
[cited968541008318486386120159
2025-08-08].114454100833468101136158195230253290326344356
European15165410083336991128167203235273
Medicines18055410083559012914517719221386100833874101
Agency.22606100834180116155187221232
Available25136100834172106121137170210226261
from:2795610083194179139151
https://www.ema.europa.eu/2967610083386085125152165192213265319374385420479512526561599621659699733746782820847
en/documents/product-information/zeposia-epar-product-information_en.pdf.21387100833473100136175208247305341380402430457495517555595633666691711727766785824846905938960976101510541080110911441184122312511266129813211358139814321454147415141536157416151653213881008331557591129148185207266298320335373411449484522535575615634646
35.2138910085367186
Ocrevus22399100834780101135167206232
(ocrelizumab)2486910083185487108142158173202240298330370387
–288891008335
Summary29379100833370128186218239273
of32259100833757
Product3296910083355693133170202227
Characteristics353791008340781101311641972212542138101008321366286101133160
(SmPC)231210100831950108144184205
[Internet].2531101008318347293127148187222244262274
[cited2818101008319496486120160
2025-08-08].299110100833569102136159196231254291326345356
European33611010083336990128167203235273
Medicines36471010083559012914521381110083314684119146
Agency.230011100834180114153185218228
Available254411100834172105120135167207222257
from:28181110083184077136148
https://www.ema.europa.eu/29821110083375983123150162189209260314367378413471503516551589610647687720733768806832
en/documents/product-information/ocrevus-epar-product-information_en.pdf.2138121008334731001361752082463053403794014294554945165535946326646897097267647838218439039369589731012105110781113114611681202123512741301132213591399143314541474151515371575161516532138131008331557591129148185207266298320335373411449484522535575615634646
36.21381410085367288
Kesimpta22421410083356996111169208230263
(ofatumumab)25201410083195574108129167225263321353392410
–2945141008335
Summary299614100833370128185218239273
of328514100833756
Product33571410083355693133170202226
Characteristics3599141008340781101311641962138151008322557792118141157189216
(SmPC)236815100831850108143184204
[Internet].2586151008318347294127149187222244262274
[cited2873151008319496486120160
2025-08-08].304615100833468101136158195231253291326344356
European34151510083336991128167203235273
Medicines3701151008355902138161008338528398135169195
Agency.234616100834077112149180213223
Available258116100834070102117131163201217251
from:28441610083183976133145
https://www.ema.europa.eu/30011610083375882120146158184204254307359369403460492505539576596633671703716750787813
en/documents/product-information/kesimpta-epar-product-information_en.pdf.213817100833472971331712032412983333713924204454825045415806176496736937087467658028238829149359509881026105210831117114311581215125412761309133113671406143914601479151915401577161616542138181008331557591129148185207266298320335373411449484522535575615634646
37.21381910085367079
Briumvi22301910083355672109166197213
(ublituximab)24551910083195493109123146183214230287319358375
–2843191008335
Summary289019100833269127184216237271
of317419100833756
Product32421910083355693132169201225
Characteristics3479191008340781101311631952192522732893152138201008322376997
(SmPC)225120100831950108144184205
[Internet].2472201008319357294128149188223245262274
[cited2763201008318486386120159
2025-08-08].293920100833468101136158195230253290326344356
European33112010083336991128167203235273
Medicines360020100835590129145177192213821100833874101
Agency.226021100834180116155187221232
Available251321100834172106121137170210226261
from:27952110083194179139151
https://www.ema.europa.eu/29672110083386085125152165192213265319374385420479512526561599621659699733746782820847
en/documents/product-information/briumvi-epar-product-information_en.pdf.213822100833473991361742082463053403794014294554935155535936316646897097257647838218439029359579731011105010771118114011561194125212841300132313601399143314541475151515371575161516532138231008331557591129148185207266298320335373411449484522535575615634646
38.21382410085367389
Brummer22482410083365796155213248270
T,253924100833342
Ruck260224100833573106136
T,275924100833342
Meuth282224100835590129151190
SG,30332410083337891
et314524100833457
al.32232410083324761
Treatment33042410083335185117139198234272294
approaches361924100833272112134171213825100833366106143171
to233125100832361
patients24152510083397497113149189212241
with26782510083526993132
multiple283325100835998115138154195212249
sclerosis31042510083276177113136175203218246
and337225100833373113
coexisting350825100833271108141157185209225265306
autoimmune21382610083337296134151211271310350386
disorders.25472610083395583122145185221244272287
Ther285626100833475111134
Adv301226100834383117
Neurol315126100834683122145183200
Disord33742610083466390130153193
2021;14:358926100833671106138147179211224
17562864211035542.21382710083346496131164198233270302334361393426459491526559571
39.21382810085367185
Konen224328100833572111146184
FF,24472810083326470
Witte25372810083577396120154
T,271128100833241
Ernst27722810083335492119142
D,293428100834556
et301028100833456
al.30862810083324760
Management316628100835487125157196231289324362384
of356928100833857
disease-modifying3646281008338537911414621382910083266184143181221236255290305343382
therapies25392910083226095116149189204239266
in282429100831452
multiple289529100835795110133148187203238
sclerosis31522910083265874108130167194208234
and340529100833270109
comorbid353329100833168127165187226242281
rheumatoid21383010083215994132190222244281296335
arthritis.24883010083325378116137153175191217230
Neurol273430100834479117138176191
Res29413010083357097
Pract30533010083355689121145
2025;7(1):48.321430100833468101136146179196227242254288324338
40.21383110085377793
Rejdak22573110083367390131165197
K,248031100833652
Szklener25583110083336396114150190227250
S,283431100833347
Korchut29073110083367699132171211235
A,316831100834258
et325231100833559
al.33373110083324963
Cladribine34263110083415892133155172213230270307
in375931100831555
myasthenia213832100835890124151175214250289305338
gravis:24973210083396094127143170183
a2701321008333
pilot27553210083395571110133
open-label290932100833878115154177194227267304320
study.32503210083275190130162173
Eur34443210083337193
J3558321008325
Neurol.360432100834581120142180196210
2020;27(3):586-589.213833100833468101135148183216232266283295330365400423457492526537
41.21383410085366880
Efficacy2231341008332506885117150182215
and245934100833169108
Safety25793410083336584118140173
of276534100833756
a2834341008331
New287834100834579130
Formulation30213410083326990148186201233254269307345
of337934100833756
Oral344734100834769101117
Cladribine35763410083405587125146162201216213835100833772
Compared222335100834077135173206227261300
With25363510083577396134
Placebo26833510083354981113147186224
in292035100831552
Participants29853510083356788112127159174213246284305332
With33303510083577396134
Generalized347735100834378116151172205220235264298337
Myasthenia213836100835688122149173213249288304337
Gravis249636100834467101133150177
(MyClad)269436100831974106149165198238259
[Internet].2974361008319357497131153193229252270283
[cited3278361008319506689124164
2025-08-11].346436100833570104139162201237261292321337350
Merck213837100835490111142172
Healthcare232637100834479111127149187219252273307
KgaA.265037100833573105147162
Available282837100834171104120135167206222257
from:31013710083194178136148
https://clinicaltrials.32663710083375983123149162189209238253268306321353386401424445461493508534548
gov/study/NCT06463587/.213838100833876108132156179217256288311357398434468504540576610643677710730736
42.21383910085367086
Sandborn223939100833265103142182220242281
WJ,25343910083577891
Rutgeerts26383910083367496134169204225250278
P,293039100833539
Feagan29833910083336799138170208
BG,32053910083358093
et331239100833456
al.33823910083324760
Natalizumab34563910083457799132147162191230287320359
induction21384010083155495134167193209248288
and244840100833372113
maintenance258240100835993109148171206246279319352387
therapy29914010083226298120155195228
for32414010083185880
Crohn’s334340100834163102142181194220
disease.35854010083395582119152179216229
N2138411008345
Engl219841100833370109125
J2338411008324
Med.237841100835489129142
2005;353:1912-1925.253541100833468104139149184217250262291322354384404435465498533545
43.21384210085367186
Targan22434210083336182120152190
SR,24524210083326781
Feagan25524210083326698137169207
BG,27784210083357993
Fedorak288942100833367106145166199229
RN,31374210083358194
et324942100833456
al.33244210083324760
ENCORE340242100833378119164200234
trial3655421008321435890106
–3779421008335
natalizumab21384310083387193127143158188227286319359
for25184310083185779
active26184310083326590105138173
Crohn’s281243100834162100140178191216
disease.30504310083385480116149176212224
Gastroenterology.329543100834478105129151189225264286320342380396435476508519
2007;132(5):1672-1683.213844100833468104137147177207239257290309321350381414449469500531566600613
44.21384510085367490
Delcoigne22444510083458196128165181219257292
B,255245100833648
Kopp261645100833573112152
TI,27844510083324961
Arkema28614510083416293127185218
EV,30944510083337180
et319045100833356
al.32624510083314760
Exposure333845100833265104143170207228262
to361645100832259
specific3691451008326651002138461008331476482114
tumour227246100832260119157196217
necrosis250946100833873106128165192207233
factor27634610083185284109146168
inhibitors29514610083155391107146162184222243271
and324246100833271110
risk3372461008321376393
of348646100833757
demyelinating35634610083397413216319821322821384710083387092107145184
and233847100833169109
inflammatory2462471008315537087119177235268289326348382
neuropathy286047100833772110131168208241263301332
in320747100831553
cohorts327647100833168106145166191219
of351147100833756
patients35834710083397293109143181203231
with21384810083526891130
inflammatory2289481008315547290123182241275297335357392
arthritis:27034810083325479119141157180196223236
a2960481008332
collaborative30144810083327086102135175215237271294310343379
observational341448100833878106142164200234256272311351384400
study21384910083264987126157
across23084910083326485122148175
five24964910083173366100
Nordic260949100834482104141156188
rheumatology28104910083215994131189221243279295333372404
registers.32274910083205494109135158191212239253
RMD349349100833590136
Open.364149100834787122160173
2023;9(1):e002924.213850100833468101136147183202234248260294330366399433466498511
45.21385110085367186
Li223851100833147
L,229851100833145
Aviña-Zubieta23565110083417187125157180216252292307342364397
JA,27665110083246478
Bernstein28575110083367192131157180214229267
CN,31375110083408598
et324851100833456
al.33175110083324760
Risk33905110083365177107
of351051100833757
Multiple358051100835492107130145184200235
Sclerosis21385210083326580115136173200215241
Among239952100834199137175214
Users263352100834470105126153
of280652100833756
Antitumor288252100834179101116138176234272294
Necrosis319652100834479112133171197212238
Factor34545210083326294118155177
α3650521008337
in370752100831553
43779521008335
Canadian213853100834073111143182197229267
Provinces:24245310083355693125141179211245272284
A2727531008341
Population-Based278753100833572112150165197219234272311333370403430465505
Study.33115310083325391130162172
Neurology.350253100834580118139176192230270302312
2023;100(6):e558-e567.213854100833468101136147177209245265298316328362397429463486522557591624630
46.3934610085367389
Konen40366100833572110145182
FF,4231610083326470
Möhn43136100835593131169
N,44946100834557
Witte4564610083577395119153
T,47296100833341
et47836100833456
al.4852610083314659
Treatment4924610083324983115136194229266288
of52246100833756
autoimmunity:52936100833269911281432002582953934710083385375109122
The40717100833372107
impact41937100831572112145177201
of44097100833756
disease-modifying4480710083385480115147173208231290328368383402437452490529
therapies5024710083226095116149188204239266
in53057100831452
multiple53727100835795110133148187203238
sclerosis3934810083265874108130167193208234
and41818100833270109
comorbid43038100833168126165186226241280
autoimmune4596810083326992129144202260297335370
disorders.4979810083385380118139177212233261274
Autoimmun52668100834178101138153211268306344
Rev.39349100833570103113
2023;22(5):103312.40629100833468101136147182217234268286298328359392425456486499
47.39341010085367079
Mason402810100835487114152190
A,423310100834155
Fragapane43021010083335285124157196229267302
L,461810100833145
Toledo-Nieves46781010083326682117156195218264280314347381408
Z,510010100833851
et516510100833457
al.52361010083324760
Use531010100834470105
of542910100833857
Calcitonin5500101008340738839341110083314668104142156193
Gene-Related414011100834378115150172209243258290311344383
Peptide453511100833568107128143181215
Monoclonal476311100835491129167199214251289321336
Antibodies51111110083407899114152190229244278304
for54281110083185576
the55161110083225994
Treatment39341210083324983114136193228266287
of423412100833756
Migraines430212100835469108129161176214248275
in458912100831552
Individuals46541210083155291106138153192229261276302
With49681210083577395133
Multiple511412100835491106128143182198232
Sclerosis.53591210083326479113134171197212238251
Int39341310083155374
J4024131008324
MS406313100835588
Care41661310083407394128
2024;26(3):104-107.430913100833468101133145180214233266283295325356393416447478511517
48.39341410085357288
Nociti403414100834482114128150165
V,421114100833544
Romozzi426714100833572129167194225240
M,451914100835467
Annovazzi459814100834178115153184216245275291
P,490114100833439
et495214100833355
al.50191410083324659
Effectiveness,50901410083325169103135159173205239276310336362375
safety,5477141008326587711039341510083225565
and401115100833270108
impact413215100831572111143175199
on434415100833775
multiple443215100835794109131146185201236
sclerosis46801510083265873108129166192207233
course492515100833268106127154189
of512615100833756
anti-CGRP51951510083326991106128170212248283
monoclonal549115100835795393416100833876108124162200233248
antibodies.41971610083327092107146185225240274301315
J4527161008324
Neurol456716100834479117138175191
Sci.4774161008332648093
2025;469:123392.488216100833468101136147181217251264294324359392425458471
49.39341710085367285
Di403917100834561
Tullio4120171008332658196111149
F,428917100833238
Odorici434617100834787125147162194210
G,457517100834457
Lasagni46521710083316591125164202217
C,488817100834053
et496117100833456
al.50371710083324760
Combination511717100833976135174189227260281297335373
treatment55101710083214377393418100833254112147185206
with41561810083516689127
secukinumab42991810083266193131161178216253311343383
and469718100833270109
dimethyl482218100833853111146168206237253
fumarate509118100831857115147168201223257
in536318100831553
a5432181008331
patient5479181008339729310939341910083347294
with40421910083506689127
psoriasis418319100833965104125141173199214240
and443819100833170109
recent45611910083215587121159181
diagnosis47561910083385385124162201227242268
of503919100833756
multiple510919100835895111133148188203238
sclerosis.53621910083265873108129167193208234248
Dermatol393420100834581102160193214251267
Ther.421720100833271106128138
2020;33(6):e13943.437020100833469101135148183216234268286298332362392425461493506
50.39342110085367287
Eksin40392110083336291106144
MA,420021100835597111
Erden43282110083335392126165
A,451021100834155
Güven458221100834482114149187
SC,47862110083327386
et488921100833456
al.49622110083324861
Secukinumab504021100833267100138168184222260317350389
in544621100831553
the55162110083216095
treatment39342210083224377108130188223261282
of422922100833756
psoriatic429822100833965103125140172194209241
arthritis45522210083315277115136151174189215
or478022100833758
ankylosing48512210083327099133149187214228266305
spondyloarthritis51692210083266510314118021222826629932034438240341939342310083223763
with40092310083516688126
multiple414823100835794110132147186201236
sclerosis:43972310083265873107129166192207233245
a4655231008331
case46992310083316490125
series4837231008326608197131158
with50082310083506588126
literature5146231008315305286107139161199220253
review.54122310083215587102137187198
Immunotherapy.393424100831573130168206244266304339361394433464474
2022;14(6):401-408.442324100833569101136149179210229262281292327363395413450486521535
51.39342510085367082
Elgenidy40332510083334887122160175214246
A,429625100834055
Elkady43682510083324777111150182
A,456725100834155
El-Dahshan46392510083324870117149187213251284322
M,497825100835467
et506225100833457
al.51362510083324760
Hypogammaglobulinemia52132510083447611615519422628434237439342610083395594134173189204243279338354387
and434226100833271111
infections44742610083155473109142167183222261288
in478326100831554
patients48582610083397396111147186208237
with51162610083516790129
multiple526726100835896112135151191208243
sclerosis55312610083276039342710083155071109135150177
treated41312710083224378110132165205
with43572710083506689127
anti-CD2045052710083317091107129172218250284
treatments:48102710083224377109131190225263285313325
a5156271008332
systematic52082710083265986110143202234256271303
review55322710083215539342810083324884136
and409228100833271111
meta-analysis422428100835894117151174207246279295327355370397
of464328100833757
19,13947212810083356677109139173
patients.49162810083397395111147186208236250
Front51872810083335492131153
Neurolw536228100834581120141179196248
2024;15:1380654.393429100833468101133145175205216246276310345381415450463
52.39343010085367187
Kolčava40383010083357288120153184217
J,427230100832436
Lasotová43253010083316591130152189221253
N,459530100834558
Vlčková46703010083355284114151183216
E,490330100833245
et496530100833456
al.50383010083324760
Validation5115301008336678297136168190205243282
of541430100833756
DYsphagia548730100834579102393431100833977109149164196
in414931100831553
MUltiple422131100835599114136152191207241
Sclerosis44823110083326580115136173200215241
questionnaire474331100833875110137160175213252290322337358392
–5155311008335
Czech520931100834071105138176
version54043110083326687115129167206
of393432100833756
DYMUS.400232100834578133176207220
Čes42353210083397299
Slov43463210083334785116
Neurol447532100834479116137173189
Neurochir467632100834579116137174206243258279
2020;83/116(3):285-290.496732100833468100134146181214238271298329347380397409443476510531562595631643
53.39343310085367186
Montalban403533100835493131153186201240273311
X,436133100833852
Gold44283310083448298137
R,458133100833549
Thompson464533100833372110168208234273311
AJ,49713310083416880
et506733100833456
al.51383310083324760
ECTRIMS/EAN521333100833373109146162217250275309351397
Guideline39343410083448196135170185200238273
on422034100833775
the43083410083215994
pharmacological441534100833877109130188220252289305343382397429462477
treatment49053410083214376108130188222260282
of520034100833756
people526934100833874112151167202
with54843410083506688126
multiple393435100835795110133148187203238
sclerosis.41873510083265874109130167194209235248
Mult445135100835492107130
Scler.45963510083326580115136146
2018;24(2):96-120.475835100833468100131143178210229263281293328364387418448482495
54.39343610085367389
Thakolwiboon404436100833372105135173189240256296335374412
S,447736100833346
Mills45433610083557086101127
EA,46913610083337690
Yang480236100833565103142
J,496536100832436
et502236100833457
al.50993610083324861
Immunosenescence518036100831573132169208246273308347382409393437100833266105138172
and412737100833271111
multiple425937100835896112135151191207242
sclerosis:45223710083276076111133171198213240253
inflammaging4796371008315537189121180239272312327366406
for52233710083195779
prognosis53233710083396199140178217245260287
and393438100833270109
therapeutic40563810083215994116149188223261283299331
consideration.440038100833168106132147186221242275297312350388401
Front48143810083335290128149
Aging.49763810083418095133172185
2023;4:1234572.517438100833468101135147181193223253288323356389423436
55.39343910085367185
van403939100833265103
der41613910083387394
Walt427539100835889104127
A,442139100834155
Strijbis4496391008333547591106145161187
EMM,470239100833388143157
Bridge,48783910083365773112151185197
F5095391008332
et514739100833456
al.52233910083324760
Advancing530339100834179112145183215230268307
multiple393440100835794109132147185201236
sclerosis41824010083265873108129166192207233
management442740100835789127159198232290324362384
in482340100831552
older48884010083375391126147
adults.504840100833170107122144172185
Nat52464010083447698
Rev535740100833569101
Neurol.5471401008344791173934411008321587487
2025;21:432-448.403641100833468101136147182213222256289321342378415451465
56.39344210085367288
Corboy40354210083407798138176208
JR,42554210083256174
Fox434242100833370100
RJ,44554210083356274
Kister45424210083355177100134155
I,471042100831427
et475042100833456
al.48194210083324760
Risk48924210083355177106
of501142100833757
new508042100833873124
disease52174210083385379114145172207
activity54374210083316387103135151393443100832155
in400143100831552
patients40654310083397193107142179200228
with43054310083506587125
multiple444343100835693108130145184199234
sclerosis46894310083265873107128165191205231
who493243100835188126
continue507143100833167105126141178215250
or533343100833758
discontinue5404431008337527811014618439344410083213774111146
disease-modifying40924410083385379113145171206229287325364379398432447485523
therapies46284410083215994115147186201236262
(DISCOMS):49034410083186479111151196250283302313
a5229441008332
multicentre,527344100835794110132147178212249270292325337
randomised,39344510083215492131169227242268303343356
single-blind,43054510083274179118134168192232247262300339352
phase467345100833877109136171
4,486045100833446
non-inferiority492245100833776114136152190209244265281318340356378412
trial.5350451008321435890106119
Lancet54844510083326510339344610083316587
Neurol.403746100834479117138175191204
2023;22(7):568-577.425746100833468101135147182217234269288300335370405428462495530536
57.39344710085367179
Coerver402647100834076112133167201222
EME,426147100833287120133
Fung440747100833268106144
WH,4564471008357102115
de469247100833772
Beukelaar477747100833570107137171186218250271
J,506147100832436
et511047100833355
al.51784710083324760
Discontinuation5250471008345618711915519321523026830533739344810083213674112
of405948100833655
First-Line4127481008332476894117137169184222256
Disease-Modifying43964810083456086120152178213235291329368383402436451489527
Therapy493648100833271105126159197228
in517748100831452
Patients52414810083356788103137175196223
With54774810083577395133
Stable39344910083325486126141176
Multiple412849100835593108130146185201235
Sclerosis:43814910083336581115137174201215241254
The465349100833372107
DOT-MS477849100834593126144200233
Randomized502949100833668106145184242257286320360
Clinical54074910083395570108123155187203
Trial.3934501008333506597113126
JAMA407550100832464120162
Neurol.425250100834580117139176192205
2025;82(2):123-131.447250100833468101136147182216233267285297326356391413444474505514
58.39345110085367288
Lee403551100833165101
S,414851100833345
Scheu420651100833365103137175
R,439451100833549
Mateen445651100835486108142177215
FJ.46845110083325163
Adults476051100834179117132154182
55495451100833567
Years50345110083356697118146
and519251100833270109
Older531451100834662101136157
with54845110083506688126
Multiple393452100835491106128143182197232
Sclerosis41785210083326479113134171197212237
(MS)442852100831871104122
Treated45635210083324982114135168207
with47835210083506587125
Ocrelizumab:492052100834779100133149163192229287318357369
Characteristics5302521008339761081291611932172502712863934531008326496597124
and407353100833169109
Outcomes419653100834785108139176234269296
Over450653100834781115136
More465753100835493114148
Than482053100833272104142
13,00049765310083346476112148184
Person-Months51745310083366990118156194217273311350371409436
(Abstract39345410083196099126149171203236260
P10-1.013).42095410083356899123154163198230260277288
Neurology.451254100834580118139176192230270302312
2025;104(7):Suppl1.483954100833469101136147177209245264299318330364401440480496528537